NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
65 trialsNCT04288687 2026-03-04
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05442749 2026-02-17
PARPi-PANC
Centre Leon Berard
Phase 2 Terminated
NCT04068753 2026-02-10
STAR
University of Oklahoma
Phase 2 Active not recruiting
NCT05700721 2026-02-05
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03601923 2026-01-28
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04992013 2026-01-23
Niraparib in Tumors Metastatic to the CNS
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04221503 2026-01-08
Niraparib/TTFields in GBM
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT05689021 2026-01-07
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Phase 2 Active not recruiting
NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
NCT04592237 2025-12-23
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04701307 2025-12-15
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05526989 2025-12-04
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT06180356 2025-11-28
ANALLISA
MedSIR
Phase 2 Recruiting
NCT05515575 2025-10-20
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06392841 2025-10-20
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT06747845 2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04030559 2025-08-26
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
University of California, Davis
Phase 2 Active not recruiting
NCT04080284 2025-08-19
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Northwell Health
Phase 2 Completed
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04493060 2025-08-07
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Completed
NCT04584255 2025-07-28
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT05297864 2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2 Terminated
NCT05455424 2025-05-15
NERO
University Hospital Southampton NHS Foundation Trust
Phase 2 Completed
NCT06212583 2025-05-01
KNIGHTS
University of Maryland, Baltimore
Phase 2 Recruiting
NCT05990192 2025-04-22
SOPRANO
Institute of Cancer Research, United Kingdom
Phase 2 Recruiting
NCT05523440 2025-03-28
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Phase 2 Terminated
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06365970 2025-02-03
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
Phase 2 Withdrawn
NCT03891576 2025-01-17
Newton
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT04507841 2024-12-17
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Tongji Hospital
Phase 2 Active not recruiting
NCT04812366 2024-12-16
GUNS
University of British Columbia
Phase 2 Recruiting
NCT05183984 2024-10-16
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
NCT04185831 2024-08-22
MEGALiT
Uppsala University Hospital
Phase 2 Active not recruiting
NCT04313504 2024-08-01
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
University of Cincinnati
Phase 2 Active not recruiting
NCT03840967 2024-06-04
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04817956 2024-02-29
IMPRESS-N
Oslo University Hospital
Phase 2 Recruiting
NCT04240106 2024-02-16
LUZERN
MedSIR
Phase 2 Completed
NCT06237205 2024-02-01
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Korea University Anam Hospital
Phase 2 Not yet recruiting
NCT03016338 2024-01-30
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Phase 2 Unknown
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT05961124 2023-11-22
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT06141265 2023-11-21
BRAND
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05174455 2023-09-18
Niraparib for the Treatment of Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed